BioSpace News Archive

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

The company uses computational modeling of cell behavior to treat disease, instead of going after a molecular target, redefining drug discovery through its cell-centric approach.

Deerfield Management-backed Jaguar Gene Therapy, and its ciliopathy-focused subsidiary Axovia Therapeutics, launched today with an undisclosed Series A.

Establishing boundaries between your personal and professional lives is the key to maintaining fulfilling versions of each.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, announced that two abstracts have been accepted for presentation at the upcoming American Association for Cancer Research Annual Meeting 2021, including two corresponding posters.

Leading NMR diagnostics company numares recently published data showing that its novel, multi-marker approach to assess kidney function allowed for a more precise estimation of glomerular filtration rate by a simple serum test.

Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, announced that it has closed a $50 million Series B financing.

ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has entered into a securities purchase agreement to raise gross proceeds of approximately $18 million resulting from the sale of its ordinary shares through a private placement to new institutional investors, Vivo Capital and Surveyor Capital

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today reported interim data from the first 20 adult patients enrolled in the ongoing Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor

Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced that The Healthcare Technology Report announced Chief Executive Officer, Scott Hutton, as one of the Top 25 Biotech CEOs of 2021.